B E Sands

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi request reprint Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease
    B E Sands
    Gastrointestinal Unit and Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Gastroenterology 117:58-64. 1999
  2. ncbi request reprint From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation
    Bruce E Sands
    Gastrointestinal Unit and Center for the Study of IBD, Massachusetts General Hospital, 55 Fruit Street, GRJ 7, Boston, Massachusetts 02114 USA
    Gastroenterology 126:1518-32. 2004
  3. ncbi request reprint The role of TNFalpha in ulcerative colitis
    Bruce E Sands
    Gastrointestinal Unit, Center for the Study of Inflammatory Bowel Diseases, and MGH Crohn s and Colitis Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    J Clin Pharmacol 47:930-41. 2007
  4. ncbi request reprint Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab
    Bruce E Sands
    Gastrointestinal Unit, MGH Crohn s and Colitis Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Inflamm Bowel Dis 13:2-11. 2007
  5. ncbi request reprint Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study
    Bruce E Sands
    Gastrointestinal Unit and Center for the Study of Inflammatory Bowel Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Clin Gastroenterol Hepatol 2:912-20. 2004
  6. ncbi request reprint Variation in severity assessment and initial mesalamine dose selection for ulcerative colitis in community practice
    Bruce E Sands
    Gastrointestinal Unit and MGH Crohn s and Colitis Center, Massachusetts General Hospital, Boston, MA, USA
    J Clin Gastroenterol 40:587-91. 2006
  7. ncbi request reprint A survey of methodological variation in the Crohn's disease activity index
    Bruce E Sands
    Gastrointestinal Unit and Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Inflamm Bowel Dis 11:133-8. 2005
  8. ncbi request reprint New therapies for the treatment of inflammatory bowel disease
    Bruce E Sands
    MGH Crohn s and Colitis Center, Gastrointestinal Unit, Massachusetts General Hospital, 165 Cambridge Street, 9th Floor, Boston, MA 02114, USA
    Surg Clin North Am 86:1045-64. 2006
  9. ncbi request reprint Algorithms to identify colonic ischemia, complications of constipation and irritable bowel syndrome in medical claims data: development and validation
    Bruce E Sands
    Gastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Pharmacoepidemiol Drug Saf 15:47-56. 2006
  10. ncbi request reprint Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease
    Bruce E Sands
    Gastrointestinal Unit and MGH Crohn s and Colitis Center, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Gastroenterol 40:482-9. 2006

Detail Information

Publications60

  1. ncbi request reprint Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease
    B E Sands
    Gastrointestinal Unit and Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Gastroenterology 117:58-64. 1999
    ..kg-1. wk-1 given 2 or 5 times weekly for 3 weeks. Clinical and laboratory safety data were recorded, and disease activity was measured at each visit...
  2. ncbi request reprint From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation
    Bruce E Sands
    Gastrointestinal Unit and Center for the Study of IBD, Massachusetts General Hospital, 55 Fruit Street, GRJ 7, Boston, Massachusetts 02114 USA
    Gastroenterology 126:1518-32. 2004
  3. ncbi request reprint The role of TNFalpha in ulcerative colitis
    Bruce E Sands
    Gastrointestinal Unit, Center for the Study of Inflammatory Bowel Diseases, and MGH Crohn s and Colitis Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    J Clin Pharmacol 47:930-41. 2007
    ..Soluble TNFalpha receptors or biologic agents that suppress or inhibit TNFalpha production may also show therapeutic promise...
  4. ncbi request reprint Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab
    Bruce E Sands
    Gastrointestinal Unit, MGH Crohn s and Colitis Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Inflamm Bowel Dis 13:2-11. 2007
    ..Natalizumab, a humanized monoclonal IgG(4) antibody to alpha4 integrin, was investigated as a treatment of active Crohn's disease (CD). The safety of natalizumab given in combination with infliximab has not previously been studied...
  5. ncbi request reprint Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study
    Bruce E Sands
    Gastrointestinal Unit and Center for the Study of Inflammatory Bowel Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Clin Gastroenterol Hepatol 2:912-20. 2004
    ..This post hoc analysis was conducted to determine the efficacy and safety of infliximab therapy in women with rectovaginal fistulas...
  6. ncbi request reprint Variation in severity assessment and initial mesalamine dose selection for ulcerative colitis in community practice
    Bruce E Sands
    Gastrointestinal Unit and MGH Crohn s and Colitis Center, Massachusetts General Hospital, Boston, MA, USA
    J Clin Gastroenterol 40:587-91. 2006
    ..The aims of this study are to assess consistency between: (1) community physicians and established treatment guidelines in their respective operational definitions of severity and (2) clinical severity ratings and resulting treatment...
  7. ncbi request reprint A survey of methodological variation in the Crohn's disease activity index
    Bruce E Sands
    Gastrointestinal Unit and Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Inflamm Bowel Dis 11:133-8. 2005
    ..The Crohn's disease activity index (CDAI) is the most widely used Crohn's disease activity instrument, yet little is known about the methodological variation in its use...
  8. ncbi request reprint New therapies for the treatment of inflammatory bowel disease
    Bruce E Sands
    MGH Crohn s and Colitis Center, Gastrointestinal Unit, Massachusetts General Hospital, 165 Cambridge Street, 9th Floor, Boston, MA 02114, USA
    Surg Clin North Am 86:1045-64. 2006
    ..As we continue to learn about how best to use the agents currently in our hands, the addition of new drugs will further improve outcomes, and will bring new insights into the fundamental causes of these diseases...
  9. ncbi request reprint Algorithms to identify colonic ischemia, complications of constipation and irritable bowel syndrome in medical claims data: development and validation
    Bruce E Sands
    Gastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Pharmacoepidemiol Drug Saf 15:47-56. 2006
    ..This report describes the development and validation of claims-based algorithms to identify colonic ischemia, hospitalized complications of constipation, and irritable bowel syndrome (IBS)...
  10. ncbi request reprint Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease
    Bruce E Sands
    Gastrointestinal Unit and MGH Crohn s and Colitis Center, Massachusetts General Hospital, Boston, MA 02114, USA
    J Clin Gastroenterol 40:482-9. 2006
    ....
  11. ncbi request reprint Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study
    B E Sands
    MGH Crohn s and Colitis Center and Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    Aliment Pharmacol Ther 23:1127-36. 2006
    ..Rapid fistula healing may predispose Crohn's disease patients to abscess development...
  12. doi request reprint A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis
    Bruce E Sands
    MGH Crohn s and Colitis Center and Gastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Gastroenterology 135:400-9. 2008
    ..Open-label studies and clinical experience in Japan and Europe have suggested that granulocyte/monocyte apheresis is safe and effective in treating ulcerative colitis...
  13. pmc Immunosuppressive drugs in ulcerative colitis: twisting facts to suit theories?
    B E Sands
    MGH Crohn s and Colitis Center, Massachusetts General and Gastrointestinal Unit Hospital, 165 Cambridge St, 9th Floor, Boston, MA 02114, USA
    Gut 55:437-41. 2006
    ..Although the evidence base in support of immunosuppressive drugs in ulcerative colitis is not as strong as in Crohn's disease, these agents clearly have a role in the treatment of this disease...
  14. doi request reprint Fulminant colitis
    Bruce E Sands
    MGH Crohn s and Colitis Center and Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, 165 Cambridge St, 9th Floor, Boston, MA 02114, USA
    J Gastrointest Surg 12:2157-9. 2008
    ..A great deal of judgment is needed to guide the timing of colectomy, but it is clear that mortality increases as the time to colectomy is prolonged...
  15. ncbi request reprint Therapy of inflammatory bowel disease
    B E Sands
    Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA
    Gastroenterology 118:S68-82. 2000
    ..This review covers agents currently used in the treatment of IBD and seeks to provide an overview of emerging therapies...
  16. ncbi request reprint Medical therapy of steroid-resistant Crohn's disease
    B E Sands
    Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Can J Gastroenterol 14:33C-37C. 2000
    ..Limited data are available on the use of tacrolimus, mycophenolate mofetil and thalidomide. Steroid-resistant Crohn's disease, while involving a small minority of patients, continues to present a difficult therapeutic challenge...
  17. doi request reprint Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease
    Bruce E Sands
    MGH Crohn s and Colitis Center and Gastrointestinal Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Inflamm Bowel Dis 16:1209-18. 2010
    ..We investigated the activity and safety of apilimod mesylate (formerly STA-5326), an oral IL-12 and IL-23 inhibitor, in patients with active CD...
  18. doi request reprint The placebo response rate in irritable bowel syndrome and inflammatory bowel disease
    Bruce E Sands
    MGH Crohn s and Colitis Center and Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Dig Dis 27:68-75. 2009
    ..In the future, improved understanding of the factors that drive the placebo response rate should lead to more efficient study design and drug development...
  19. ncbi request reprint Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease
    B E Sands
    Gastrointestinal Unit and Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital, Boston, 02114, USA
    Aliment Pharmacol Ther 16:399-406. 2002
    ..Interleukin-11 is a mesenchymally derived cytokine with pleiotropic activities. A pilot study suggested therapeutic benefit of recombinant human interleukin-11 (rhIL-11) in patients with Crohn's disease...
  20. ncbi request reprint Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study
    B E Sands
    Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital, Boston 02114, USA
    Inflamm Bowel Dis 7:83-8. 2001
    ..Infusion with infliximab produced no significant adverse events. Infliximab was well tolerated and may provide clinical benefit for some patients with steroid-refractory ulcerative colitis...
  21. ncbi request reprint Review article: Medical therapy for fistulizing Crohn's disease
    B Bressler
    Gastrointestinal Unit and MGH Crohn s and Colitis Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Aliment Pharmacol Ther 24:1283-93. 2006
    ..With an expected spontaneous healing rate of only 10%, fistulizing Crohn's disease requires a comprehensive strategy with a medical and possible surgical approach...
  22. ncbi request reprint Infliximab maintenance therapy for fistulizing Crohn's disease
    Bruce E Sands
    Gastrointestinal Unit, Massachusetts General Hospital, and Harvard Medical School, Boston 02114, USA
    N Engl J Med 350:876-85. 2004
    ..It is not known whether infliximab is an effective maintenance therapy for patients with fistulas...
  23. ncbi request reprint Biologicals: principles, techniques and mechanisms of action
    B E Sands
    Gastrointestinal Unit and Center for the Study of IBD, Massachusetts General Hospital, Boston, USA
    Acta Gastroenterol Belg 64:165-9. 2001
    ..This paper is intended to highlight the methodological principles behind biologic agents, methods of discovery and production, and to highlight potential therapeutic targets for these new agents...
  24. ncbi request reprint Biological therapies for ulcerative colitis
    B E Sands
    Gastrointestinal Unit and Center for the Study of IBD, Massachusetts General Hospital, Boston, USA
    Acta Gastroenterol Belg 64:205-9. 2001
    ..The role of probiotic therapy, and studies of cytokine-directed therapies, therapies targeting adhesion and recruitment, and restitution and repair are described...
  25. ncbi request reprint Effects of growth hormone secretion on body composition in patients with Crohn's disease
    Laurence Katznelson
    Neuroendocrine Unit and General Clinical Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    J Clin Endocrinol Metab 88:5468-72. 2003
    ..These data show that GH has an important role in modulating visceral fat distribution in patients with Crohn's disease...
  26. doi request reprint Validation of the functional assessment of chronic illness therapy-fatigue (FACIT-F) in patients with inflammatory bowel disease
    A Tinsley
    Dr Henry D Janowitz Division of Gastroenterology, Mount Sinai School of Medicine, NY 10029, USA
    Aliment Pharmacol Ther 34:1328-36. 2011
    ..76, 95% CI -0.89 to -0.50), CRP (-0.72, 95% CI -0.88 to -0.43) and HCT (0.53, 95% CI 0.22-0.74). CONCLUSION  The FACIT-F scale is a reliable and valid instrument for measuring fatigue in IBD...
  27. ncbi request reprint Acute and late toxicity of patients with inflammatory bowel disease undergoing irradiation for abdominal and pelvic neoplasms
    C G Willett
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Int J Radiat Oncol Biol Phys 46:995-8. 2000
    ..To clarify the use of this modality in this setting, this study assesses the short- and long-term tolerance of 28 patients with IBD to abdominal and pelvic irradiation...
  28. doi request reprint Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications
    Hiroko Kunitake
    Department of Surgery, Massachusetts General Hospital, 15 Parkman Street, ACC 460, Boston, MA 02114, USA
    J Gastrointest Surg 12:1730-6; discussion 1736-7. 2008
    ..We examined a large patient cohort to clarify whether a relationship exists between IFX and postoperative complications...
  29. ncbi request reprint Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis
    G G Kaplan
    Massachusetts General Hospital, Gastrointestinal Unit, Boston, MA, USA
    Aliment Pharmacol Ther 26:1509-20. 2007
    ..Crohn's disease patients who have lost response to 5 mg/kg of infliximab may regain response by increasing the dose of infliximab to 10 mg/kg. Alternatively, adalimumab can be used as a rescue therapy...
  30. pmc Inflammatory bowel disease: past, present, and future
    Bruce E Sands
    MGH Crohn s and Colitis Center and Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, 165 Cambridge Street, 9th Floor, Boston, MA 02114, USA
    J Gastroenterol 42:16-25. 2007
    ..Future directions in the IBD will likely explicate the inhomogeneous causes of these diseases, with implications for individualized therapy...
  31. ncbi request reprint Risk factors for colorectal cancer in Crohn's colitis: a case-control study
    Corey A Siegel
    Section of Gastroenterology and Hepatology, Inflammatory Bowel Disease Center, Dartmouth Medical School, Lebanon, NH, and Gastrointestinal Unit, MGH Crohn s and Colitis Center, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
    Inflamm Bowel Dis 12:491-6. 2006
    ..Few data exist regarding exposures associated with colorectal cancer (CRC) in patients with Crohn's colitis. The aim of this study was to identify exposures that alter the risk of CRC in patients with Crohn's colitis...
  32. ncbi request reprint Guidelines for immunizations in patients with inflammatory bowel disease
    Bruce E Sands
    Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Inflamm Bowel Dis 10:677-92. 2004
    ..We conclude that for most patients with IBD, recommendations for immunization do not deviate from recommended schedules for the general population...
  33. doi request reprint Validation of interactive voice response system administration of the Short Inflammatory Bowel Disease Questionnaire
    Manuel Y Lam
    MGH Crohn s and Colitis Center and Gastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Inflamm Bowel Dis 15:599-607. 2009
    ..We assessed the validity of an interactive voice response system (IVRS) as a new mode of administering the SIBDQ...
  34. ncbi request reprint Why do anti-tumor necrosis factor antibodies work in Crohn's disease?
    Bruce E Sands
    Gastrointestinal Unit and MGH Inflammatory Bowel Disease Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Rev Gastroenterol Disord 4:S10-7. 2004
    ..Transmembrane binding of TNF effects apoptosis of T cells, thereby alleviating a fundamental defect in Crohn's disease in the regulation of T cell populations...
  35. ncbi request reprint Review article: practical management of inflammatory bowel disease patients taking immunomodulators
    C A Siegel
    Gastrointestinal Unit and MGH Crohn s and Colitis Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Aliment Pharmacol Ther 22:1-16. 2005
    ..Immunomodulators are important agents for the treatment of Crohn's disease and ulcerative colitis, and prescribing clinicians should be comfortable recognizing both their value and their limitations...
  36. ncbi request reprint Outcome of surgical versus percutaneous drainage of abdominal and pelvic abscesses in Crohn's disease
    Alexandra Gutierrez
    Gastrointestinal Unit and MGH Crohn s and Colitis Center, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Am J Gastroenterol 101:2283-9. 2006
    ..Abdominal and pelvic abscesses are a common complication of Crohn's disease. We studied the effect of the initial choice of therapy on time to resolution of abdominal and pelvic abscesses...
  37. pmc Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis
    Corey A Siegel
    Dartmouth Hitchcock IBD Center and Section of Gastroenterology and Hepatology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, Massachusetts, USA
    Clin Gastroenterol Hepatol 7:874-81. 2009
    ....
  38. ncbi request reprint Design issues and outcomes in IBD clinical trials
    Bruce E Sands
    Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Inflamm Bowel Dis 11:S22-8. 2005
    ..Careful subject selection, standardization of disease activity indices, and precise outcome measurement are the keys to continued improvement of the inflammatory bowel disease research process...
  39. pmc Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease
    D G Forcione
    Gastrointestinal Unit and Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Gut 53:1117-22. 2004
    ..We sought to explore the role of ASCA as a prognostic marker for aggressive disease phenotype in Crohn's disease...
  40. pmc The risk of developing Crohn's disease after an appendectomy: a population-based cohort study in Sweden and Denmark
    Gilaad G Kaplan
    MGH Crohn s and Colitis Center, Boston, Massachusetts, USA
    Gut 56:1387-92. 2007
    ..The relationship between appendectomy and Crohn's disease is controversial. A Swedish-Danish cohort study was conducted to assess the risk of developing Crohn's disease after an appendectomy...
  41. ncbi request reprint Risk of early surgery for Crohn's disease: implications for early treatment strategies
    Bruce E Sands
    Gastrointestinal Unit and Center for the Study of IBD, Department of Medicine, Massachusetts General Hospital, 55 Fruit Street, GRJ 7, Boston, MA 02114, USA
    Am J Gastroenterol 98:2712-8. 2003
    ..In this study we aimed to define the rate of early surgery for Crohn's disease and to identify risk factors associated with early surgery as a basis for subsequent studies of early intervention in Crohn's disease...
  42. pmc Treatment with a broad-spectrum cephalosporin versus piperacillin-tazobactam and the risk for isolation of broad-spectrum cephalosporin-resistant Enterobacter species
    Mitchell J Schwaber
    Department of Medicine, Beth Israel Deaconess Medical Center and Massachusetts General Hospital, Boston, Massachusetts, USA
    Antimicrob Agents Chemother 47:1882-6. 2003
    ..and the equivalence in risk associated with piperacillin-tazobactam and broad-spectrum cephalosporins may have important clinical and epidemiologic implications...
  43. pmc LRRK2 is involved in the IFN-gamma response and host response to pathogens
    Agnès Gardet
    Center for the Study of the Inflammatory Bowel Disease, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Immunol 185:5577-85. 2010
    ..These observations indicate that LRRK2 is an IFN-γ target gene, and it might be involved in signaling pathways relevant to Crohn's disease pathogenesis...
  44. ncbi request reprint Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride
    David P Miller
    Ingenix, Epidemiology Division, Newton, Massachusetts 02466, USA
    Am J Gastroenterol 98:1117-22. 2003
    ..We sought to compare the incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery among alosetron users and a cohort of patients with IBS who did not use alosetron...
  45. ncbi request reprint State of the art: IBD therapy and clinical trials in IBD
    Kim L Isaacs
    University of North Carolina, Chapel Hill, North Carolina, USA
    Inflamm Bowel Dis 11:S3-12. 2005
    ..The number of products under development and continued investigations into the pathogenesis of IBD emphasize the need to expand clinical research efforts in IBD...
  46. ncbi request reprint Occurrence of colon ischemia in relation to irritable bowel syndrome
    J Alexander Cole
    Ingenix Epidemiology, Newton, Massachusetts 02466, USA
    Am J Gastroenterol 99:486-91. 2004
    ..S. market in part because of the occurrence of colon ischemia in treated patients. Since the relation between colon ischemia and IBS is poorly understood, we evaluated the incidence of colon ischemia among people with and without IBS...
  47. pmc Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial
    James D Lewis
    Division of Gastroenterology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Gastroenterology 134:688-95. 2008
    ..Thiazolidinedione ligands for the gamma subtype of peroxisome proliferator-activated receptors (PPARgamma), widely used to treat type 2 diabetes mellitus, have been proposed as novel therapies for ulcerative colitis (UC)...
  48. ncbi request reprint Risks and benefits of infliximab for the treatment of Crohn's disease
    Corey A Siegel
    Section of Gastroenterology and Hepatology, Inflammatory Bowel Disease Center, Dartmouth Hitchcock Medical Center, Dartmouth Medical School, Lebanon, New Hampshire, USA
    Clin Gastroenterol Hepatol 4:1017-24; quiz 976. 2006
    ..The purpose of this study was to analyze the risks and benefits of infliximab for the treatment of Crohn's disease with the goal of providing data to aid both physicians and patients in the process of making a decision about treatment...
  49. ncbi request reprint Selective leukocyte apheresis for the treatment of inflammatory bowel disease
    Maria T Abreu
    Inflammatory Bowel Disease Center, New York, NY, USA
    J Clin Gastroenterol 41:874-88. 2007
    ..Despite these findings, large controlled trials of selective leukocyte apheresis in the treatment of IBD are needed to determine the true efficacy of this approach...
  50. ncbi request reprint A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis
    Milton D Rossman
    Hospital of the University of Pennsylvania, Philadelphia, PA, USA
    Sarcoidosis Vasc Diffuse Lung Dis 23:201-8. 2006
    ..To evaluate the safety and tolerability of infliximab in the treatment of active pulmonary sarcoidosis, and to provide an initial assessment of the efficacy of infliximab in the treatment of active pulmonary sarcoidosis...
  51. ncbi request reprint Risk factors for colon ischemia
    Alexander M Walker
    Ingenix Epidemiology, Auburndale, Massachusetts 02466, USA
    Am J Gastroenterol 99:1333-7. 2004
    ..To identify predictors of colon ischemia, we examined demographic and clinical characteristics of patients, as well as their prior health care utilization...
  52. ncbi request reprint Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease
    Gary R Lichtenstein
    Division of Gastroenterology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA
    Gastroenterology 128:862-9. 2005
    ..We examined the effect of infliximab maintenance treatment on hospitalizations, surgeries, and procedures in patients with fistulizing Crohn's disease enrolled in the ACCENT II study...
  53. ncbi request reprint Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy
    F Reed Johnson
    Research Triangle Institute RTI International, Research Triangle Park, North Carolina, USA
    Gastroenterology 133:769-79. 2007
    ..The aim of this study is to estimate the willingness of Crohn's disease (CD) patients to accept life-threatening adverse event risks in exchange for CD symptom relief...
  54. ncbi request reprint Infliximab for induction and maintenance therapy for ulcerative colitis
    Paul Rutgeerts
    University Hospital Gasthuisberg, Leuven, Belgium
    N Engl J Med 353:2462-76. 2005
    ..Infliximab, a chimeric monoclonal antibody directed against tumor necrosis factor alpha, is an established treatment for Crohn's disease but not ulcerative colitis...
  55. doi request reprint Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis
    Gilaad G Kaplan
    Inflammatory Bowel Disease Clinic, University of Calgary, Calgary, Alberta, Canada
    Gastroenterology 134:680-7. 2008
    ..We set out to evaluate postoperative morbidity and mortality using a nationally representative database and to determine the factors that influenced outcomes...
  56. ncbi request reprint American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006
    Michael Clark
    Department of Pathology, Cambridge University, Cambridge, England
    Gastroenterology 133:312-39. 2007
    ..Abbott Laboratories representatives did not attend the conference, nor did they participate in any way in the development of this report...
  57. ncbi request reprint Acute appendicitis following colonoscopy
    Michael J Rosen
    J Clin Gastroenterol 39:78. 2005
  58. ncbi request reprint Prevention and treatment of osteoporosis in inflammatory bowel disease
    Gary R Lichtenstein
    University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania, Gastroenterology Division, Department of Medicine, Philadelphia, PA 19104 4283, USA
    Inflamm Bowel Dis 12:797-813. 2006
    ..They should not be interpreted as quality standards...
  59. ncbi request reprint Possible association between isotretinoin and inflammatory bowel disease
    Deepa Reddy
    Department of Medicine, University of Chicago, Chicago, Illinois, USA
    Am J Gastroenterol 101:1569-73. 2006
    ..Our aim was to perform a systematic examination of reports of IBD associated with isotretinoin use...
  60. ncbi request reprint Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease
    Corey A Siegel
    Inflammatory Bowel Disease Center, Section of Gastroenterology and Hepatology, Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, USA
    Inflamm Bowel Dis 14:1-6. 2008
    ..The aim of this study was to determine patients' and parents' perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease (IBD)...

Research Grants4

  1. IMMUNOMODULATION IN INFLAMMATORY BOWEL DISEASE
    BRUCE SANDS; Fiscal Year: 2004
    ..The principal investigator seeks to become an independent clinical investigator by completing the didactic and scientific portions of this proposal. ..
  2. IMURAN Dose Ranging Study in Crohn's Disease
    BRUCE SANDS; Fiscal Year: 2005
    ..Abstract Not Provided ..
  3. OSCCAR: A Novel, Population-based Prospective Inception Cohort of Inflammatory Bo
    BRUCE SANDS; Fiscal Year: 2007
    ..We will follow these patients over time to determine the progression of their disease and to compare this to markers in the blood as a way of developing a system to predict the individual course of disease. ..